JP2020502106A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020502106A5 JP2020502106A5 JP2019531623A JP2019531623A JP2020502106A5 JP 2020502106 A5 JP2020502106 A5 JP 2020502106A5 JP 2019531623 A JP2019531623 A JP 2019531623A JP 2019531623 A JP2019531623 A JP 2019531623A JP 2020502106 A5 JP2020502106 A5 JP 2020502106A5
- Authority
- JP
- Japan
- Prior art keywords
- bipolar disorder
- pharmaceutical composition
- formula
- group
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20160170224 | 2016-12-14 | ||
| KR10-2016-0170224 | 2016-12-14 | ||
| PCT/KR2017/014740 WO2018111008A1 (ko) | 2016-12-14 | 2017-12-14 | 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020502106A JP2020502106A (ja) | 2020-01-23 |
| JP2020502106A5 true JP2020502106A5 (enExample) | 2021-01-14 |
| JP7208139B2 JP7208139B2 (ja) | 2023-01-18 |
Family
ID=62559442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531623A Active JP7208139B2 (ja) | 2016-12-14 | 2017-12-14 | 双極性障害の予防、軽減又は治療のためのカルバメート化合物の使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11571410B2 (enExample) |
| EP (1) | EP3556366B1 (enExample) |
| JP (1) | JP7208139B2 (enExample) |
| KR (1) | KR102635938B1 (enExample) |
| CN (1) | CN110290788A (enExample) |
| AU (1) | AU2017374458B2 (enExample) |
| BR (1) | BR112019011930A2 (enExample) |
| CL (1) | CL2019001618A1 (enExample) |
| ES (1) | ES3054693T3 (enExample) |
| IL (1) | IL267195B2 (enExample) |
| MX (1) | MX2019006940A (enExample) |
| MY (1) | MY199104A (enExample) |
| WO (1) | WO2018111008A1 (enExample) |
| ZA (1) | ZA201903747B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL281559B2 (en) * | 2018-09-21 | 2025-06-01 | Sk Biopharmaceuticals Co Ltd | (r)-1-phenyl-2-tetrazolyl ethyl carbamate derivatives and formulations comprising same for use in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder |
| CN113242735A (zh) * | 2018-09-21 | 2021-08-10 | 爱思开生物制药株式会社 | 使用氨基甲酸酯化合物预防、缓解或治疗并发的癫痫发作 |
| AU2020389425B2 (en) * | 2019-11-22 | 2026-03-05 | Sk Biopharmaceuticals Co., Ltd. | Oral pharmaceutical composition comprising carbamate compound and preparation method therefor |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ID28529A (id) * | 1997-08-14 | 2001-05-31 | Hoffmann La Roche | Vinileter heterosiklik untuk gangguan neurologi |
| US6555585B2 (en) | 2000-07-21 | 2003-04-29 | Teva Pharmaceutical Industries, Ltd. | Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder |
| DE60223506T2 (de) * | 2001-02-27 | 2008-09-18 | Ortho-Mcneil Pharmaceutical, Inc. | Carbamatverbindungen zur vorbeugung oder behandlung bipolarer erkrankungen |
| HUP0303243A3 (en) * | 2001-02-27 | 2012-07-30 | Ortho Mcneil Pharm Inc | Carbamate compounds for use in preventing and treating bipolar disorder |
| EP2623095A1 (en) | 2004-11-16 | 2013-08-07 | Elan Pharma International Limited | Injectable nanoparticulate olanzapine formulations |
| US7598279B2 (en) * | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
| JP2010508354A (ja) * | 2006-10-31 | 2010-03-18 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 広汎性発達障害の処置 |
| AU2009348523B2 (en) | 2009-06-22 | 2015-02-26 | Sk Biopharmaceuticals Co., Ltd. | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester |
| US8404461B2 (en) | 2009-10-15 | 2013-03-26 | SK Biopharmaceutical Co. Ltd. | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| EP3180329B1 (en) | 2014-08-15 | 2020-03-18 | Janssen Pharmaceuticals, Inc. | Triazoles as nr2b receptor inhibitors |
-
2017
- 2017-12-14 CN CN201780077574.0A patent/CN110290788A/zh active Pending
- 2017-12-14 WO PCT/KR2017/014740 patent/WO2018111008A1/ko not_active Ceased
- 2017-12-14 KR KR1020197018408A patent/KR102635938B1/ko active Active
- 2017-12-14 EP EP17881161.8A patent/EP3556366B1/en active Active
- 2017-12-14 JP JP2019531623A patent/JP7208139B2/ja active Active
- 2017-12-14 US US16/468,782 patent/US11571410B2/en active Active
- 2017-12-14 ES ES17881161T patent/ES3054693T3/es active Active
- 2017-12-14 MX MX2019006940A patent/MX2019006940A/es unknown
- 2017-12-14 BR BR112019011930-2A patent/BR112019011930A2/pt not_active Application Discontinuation
- 2017-12-14 IL IL267195A patent/IL267195B2/en unknown
- 2017-12-14 AU AU2017374458A patent/AU2017374458B2/en active Active
- 2017-12-14 MY MYPI2019003348A patent/MY199104A/en unknown
-
2019
- 2019-06-11 ZA ZA2019/03747A patent/ZA201903747B/en unknown
- 2019-06-12 CL CL2019001618A patent/CL2019001618A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512531A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| JP2024543976A5 (enExample) | ||
| JP2016518437A5 (enExample) | ||
| JP2017527532A5 (enExample) | ||
| RU2015143610A (ru) | Лечение катаплексии | |
| JP2015532295A5 (enExample) | ||
| JP2019516739A5 (enExample) | ||
| JP2016040288A5 (enExample) | ||
| JP2009541223A5 (enExample) | ||
| JP2017511360A5 (enExample) | ||
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| JP2014511891A5 (enExample) | ||
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| JP2015511609A5 (enExample) | ||
| JP2016503797A5 (enExample) | ||
| JP2019535723A5 (enExample) | ||
| RU2018113718A (ru) | Новые соединения | |
| JP2019529444A5 (enExample) | ||
| JP2019520344A5 (enExample) | ||
| JP2011509302A5 (enExample) | ||
| JP2021504384A5 (enExample) | ||
| JP2016537432A5 (enExample) | ||
| RU2011147186A (ru) | 2, 5-дизамещенные арилсульфонамидные антагонисты ссr3 | |
| JP2011518168A5 (enExample) |